EUVIMEDEUVIMED entdecken
Crossref

CTSG Suppresses Breast Cancer Progression by Inhibiting the EGFR/ERK Signaling Pathway and Enhancing CD8⁺ T Cell Activation

Yue Pan, Chenhui Zheng, Danni Zheng, Yin Pan

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2026.07.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Yue Pan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China. Hauptthemen laut MEDLINE: Breast Neoplasms, CD8-Positive T-Lymphocytes, MAP Kinase Signaling System. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Taizhou Municipal Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Breast cancer (BC), the most common female malignancy, has metastasis as its main cause of mortality. Cathepsin G (CTSG) is involved in tumorigenesis and immunity. This study explores the role of CTSG in BC progression and CD8 + T cell regulation. METHODS: Differentially expressed genes and proteins (DEGs/DEPs) were analyzed using Limma, and core genes were screened using Random Forest (RF) and Least absolute shrinkage and selection operator (LASSO). CTSG expression was analyzed using GSE36295, the Cancer Genome Atlas (TCGA), reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and western blot. Cell viability, proliferation, cell cycle, migration, and invasion were detected using Cell Counting Kit-8 (CCK8), 5‑Ethynyl‑2'‑deoxyuridine (EdU), flow cytometry, and Transwell assays, respectively. Sphere diameter was analyzed via sphere formation assay. Downstream mechanisms were examined using western blot, CCK8, flow cytometry, and Transwell assays. CD8 + T cell activity was examined using EdU, western blot, and flow cytometry. RESULTS: A total of 177 genes overlapped between GSE36295 DEGs and PDC000173 DEPs. CTSG was the hub gene identified by RF and LASSO. CTSG expression was significantly reduced in BC (P < 0.01). CTSG overexpression suppressed cell viability, proliferation, migration, invasion, sphere formation, and CD44 and CD133 expression (P < 0.01). CTSG up-regulation inhibited epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) signaling axis and reduced cancer cell malignancy (P < 0.01). CTSG overexpression activated CD8 + T cells via EGFR/ERK inhibition, enhancing their cytotoxic effect on cancer cells (P < 0.01). CONCLUSION: CTSG inhibits BC malignancy and enhances CD8 + T cell function via EGFR/ERK inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCD8-Positive T-LymphocytesMAP Kinase Signaling SystemHumansFemaleErbB ReceptorsCell ProliferationDisease ProgressionCell MovementGene Expression Regulation, NeoplasticLymphocyte ActivationCell Line, Tumor

Stichwörter der Autor:innen

Cathepsin GImmunomodulationMammary neoplasmsSerine proteasesTumor progression

Substanzen

ErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
  • Department of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China. Electronic address: as77001199@163.com.

Förderung

  • Taizhou Municipal Science and Technology Bureau

Zitieren

APA

Pan, Y., Zheng, C., Zheng, D., & Pan, Y. (2026). CTSG Suppresses Breast Cancer Progression by Inhibiting the EGFR/ERK Signaling Pathway and Enhancing CD8⁺ T Cell Activation. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.07.027

Vancouver

Pan Y, Zheng C, Zheng D, Pan Y. CTSG Suppresses Breast Cancer Progression by Inhibiting the EGFR/ERK Signaling Pathway and Enhancing CD8⁺ T Cell Activation. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.07.027

BibTeX
@article{Pan2026,
  author = {Pan, Yue and Zheng, Chenhui and Zheng, Danni and Pan, Yin},
  title = {CTSG Suppresses Breast Cancer Progression by Inhibiting the EGFR/ERK Signaling Pathway and Enhancing CD8⁺ T Cell Activation},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2026.07.027}
}
Kostenlos starten →